(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 October 2021 (21.10.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/209822 A1

(51) International Patent Classification:
A61P 13/12 (2006.01) *A61K 38/17* (2006.01)

(21) International Application Number:
PCT/IB2021/000282

(22) International Filing Date:
15 April 2021 (15.04.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/011,048 16 April 2020 (16.04.2020) US
63/092,072 15 October 2020 (15.10.2020) US
PCT/IB2021/000021 07 January 2021 (07.01.2021) IB

(71) Applicant: **ABIONYX PHARMA SA** [FR/FR]; 33-43 Avenue Georges Pompidou, Batiment D2, 31130 Balma (FR).

(72) Inventors: **DASSEUX, Jean-Louis**; 7 Allees Charles Malpel, Bât. B., 31300 Toulouse (FR). **CALABRESI, Laura**; Via Balzaretti 9, 20133 Milano (IT). **TUPIN, Cyrille**; c/o Abionyx Pharma SA, 33-43 Avenue Georges Pompidou, Batiment D2, 31130 Balma (FR). **BARBARAS, Ronald**; c/o Abionyx Pharma SA, 33-43 Avenue Georges Pompidou, Batiment D2, 31130 Balma (FR). **PEYROTTES, Constance**; c/o Abionyx Pharma SA, 33-43 Avenue Georges Pompidou, Batiment D2, 31130 Balma (FR).

(74) Agent: **HOFFMANN EITLE PATENT- UND RECHTSANWÄLTE PARTMBB, ASSOCIATION NO. 151**; Arabellastraße 30, 81925 Munich (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: CER-001 THERAPY FOR TREATING KIDNEY DISEASE




Fig. 1

(57) Abstract: CER-001 for treating kidney disease, and methods for treating a subject having kidney disease with CER-001.

WO 2021/209822 A1

[Continued on next page]

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*